Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 prevalence of aGVHD and cGVHD in AML patients

From: Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)

aGVHD

cGVHD

 

Patient a-GVHD +

(Number, %)

Patient a-GVHD−

(Number, %)

Patient cGVHD+

(Number, %)

Patient cGVHD−

(Number, %)

KIR/HLA m (number, %)

8 (33%)

16 (67%)

4 (17%)

20 (83%)

KIR/HLA mm

17 (57%)

13 (43%)

8 (27%)

22 (73%)

Total

25 (46%)

29 (54%)

12 (22%)

42 (78%)

  1. aGVHD acute graft versus host disease, cGVHD chronic graft versus host disease, m match, mm mismatch
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us